MAP2K7 and neoplasm: In all five patients, additional MAPK-activating alterations, including NRAS and MEK2 mutations, were acquired in the matched tumours progressing on BRAF inhibitor monotherapy or BRAF/MEK inhibitor combination treatment (Table S2).